NSC 405020

Pricing Availability   Qty
Description: Histone deacetylase inhibitor
Chemical Name: 3,4-Dichloro-N-(1-methylbutyl)benzamide
Purity: ≥99% (HPLC)
Citations (5)
Literature (4)

Biological Activity for NSC 405020

NSC 405020 is a membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor (IC50 > 100 μmol/L). Directly interacts with the hemopexin domain (PEX) of MT1-MMP, affecting homodimerization and repressing its pro-tumorigenic activity in vivo. Displays no effect on the catalytic activity of MT1-MMP or MMP-2.

Compound Libraries for NSC 405020

NSC 405020 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.

Technical Data for NSC 405020

M. Wt 260.16
Formula C12H15Cl2NO
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 7497-07-6
PubChem ID 346721
Smiles ClC1=CC=C(C(NC(C)CCC)=O)C=C1Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for NSC 405020

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 26.02 100
ethanol 26.02 100

Preparing Stock Solutions for NSC 405020

The following data is based on the product molecular weight 260.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.84 mL 19.22 mL 38.44 mL
5 mM 0.77 mL 3.84 mL 7.69 mL
10 mM 0.38 mL 1.92 mL 3.84 mL
50 mM 0.08 mL 0.38 mL 0.77 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for NSC 405020

References are publications that support the biological activity of the product.

Remacle et al (2012) Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 72 2339 PMID: 22406620

If you know of a relevant reference for NSC 405020, please let us know.

View Related Products by Product Action

View all Class I HDAC Inhibitors

Keywords: NSC 405020, NSC 405020 supplier, NSC405020, Membrane, type-1, matrix, metalloproteinase, MT1-MMP, inhibitors, inhibits, hemopexin, domains, PEX, pro-tumorigenic, antitumor, MMP2, MMP-2, MMP, Matrix, Metalloprotease, Class, I, HDACs, 4902, Tocris Bioscience

5 Citations for NSC 405020

Citations are publications that use Tocris products. Selected citations for NSC 405020 include:

Isabelle et al (2020) Basement membrane remodelling regulates mouse embryogenesis. Nature 582 253-258 PMID: 32523119

Kumar et al (2018) MMP Secretion Rate and Inter-invadopodia Spacing Collectively Govern Cancer Invasiveness. Biophys J 114 650 PMID: 29414711

Clancy et al (2015) Regulated delivery of molecular cargo to invasive tumour-derived microvesicles. Proc Natl Acad Sci U S A 6 6919 PMID: 25897521

Helena et al (2017) Mesenchymal stem cells differentially affect the invasion of distinct glioblastoma cell lines. Oncotarget 8 25482-25499 PMID: 28424417

Do you know of a great paper that uses NSC 405020 from Tocris? Please let us know.

Reviews for NSC 405020

There are currently no reviews for this product. Be the first to review NSC 405020 and earn rewards!

Have you used NSC 405020?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.